Latest news with #Theralase
Associated Press
a day ago
- Business
- Associated Press
Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ('AGSM') to take place on Wednesday, June 11 th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada. In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed. The corporate power point presentation and question and answer period will end at 6:30 pm ET. Zoom Meeting Link: Webinar ID: 871 7513 9183 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom. An archived version will be available on the website, the next business day, following the conference call. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Globe and Mail
7 days ago
- Business
- Globe and Mail
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase®" or the " Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements (" Financial Statements"). Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025. Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to mperraton@ An archived version will be available on the website following the conference call. 1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income To view an enhanced version of this graphic, please visit: Financial Highlights For the three-month period ended March 31, 2025: Total revenue was $91,190, compared to $175,554 in Q1 2024, a 48% year-over-year decrease. Cost of sales was $77,896 (85% of revenue), resulting in a gross margin of $13,294 (15% of revenue), down from $62,114 (35% of revenue) in Q1 2024. Selling expenses were $68,143, essentially flat compared to $67,552 in the prior year. Administrative expenses rose to $555,074 from $511,495, a 9% increase driven primarily by professional fees and stock-based compensation. Research and development expenses were $877,670, up from $756,380, reflecting increased activity to support Study II progress. Net loss for the period was $1,471,250, compared to $1,266,711 in Q1 2024. This includes $220,538 in non-cash charges such as amortization and stock-based compensation. Operational Highlights Private Placements On March 10, 2025, the Company closed a non-brokered private placement of 1,034,002 units at $0.30 per unit for gross proceeds of $310,201. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at $0.45 for five years. Net proceeds were $304,633, after transaction costs. On April 22, 2025, the Company completed another non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years. The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws. Herpes Simplex Virus ("HSV") Treatment Program Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice (" GLP") toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved. Phase II Bladder Cancer Study Update ("Study II") 82 patients have been treated with the Study Procedure, representing approximately 91% of the total targeted enrollment of 90 evaluable patients. 69 patients have completed their 90-day assessment and are considered evaluable for interim efficacy analysis. 13 additional patients are pending their 90-day assessment and will be included in future efficacy updates once evaluations are complete. Interim Clinical Results For the primary endpoint of Study II (Complete Response (" CR") at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response (" IR") (negative cystoscopy and positive or suspicious urine cytology), the Total Response ("TR") increases to 70%. This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer. For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure). For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events (" SAEs") directly related to the Study Drug or Study Device. Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years. Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase. Theralase® is on track to complete enrollment in Study II by the summer of 2025. This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026. Upon follow-up of all patients, the Company plans to submit a New Drug Application ("NDA") to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027. As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®. To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning: Licensing of the light-activated Ruvidar® for BCG-Unresponsive NMIBC CIS Collaborative research focused on investigating light-activated Ruvidar® in the treatment of NMIBC Collaborative research focused on combining Ruvidar® with other FDA approved drugs In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases. Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time. Additional Oncology Targets Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®. Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers. Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the "tumour's damage zone" and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body. Rutherrin®, if clinically proven, will be able to "hunt" and "localize" into cancer cells and when activated by radiation "destroy" them; wherever, they may reside in the body. The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications: 1) Glio Blastoma Multiforme (" GBM") Brain Cancer Treatment 2) Non-Small Cell Lung Cancer (" NSCLC") Treatment 3) Pancreatic Cancer 4) Colorectal Cancer 5) Muscle Invasive Bladder Cancer (" MIBC") Treatment 6) Herpes Simplex Virus (" HSV-1") Topical Treatment for Cold Sore Lesions For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at About Ruvidar®: Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements (" FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words " may, " should", " will", " anticipates", " believes", " plans", " expects", " estimate", " potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
The Market Online
28-04-2025
- Business
- The Market Online
Theralase uncovers new use-case for flagship drug
Healthcare stock Theralase Technologies (TSXV:TLT) recently discovered that its lead drug candidate, Ruvidar, has the potential to inhibit deubiquitinating enzymes, which are linked to certain cancers and neurodegenerative diseases Theralase is a clinical-stage pharmaceutical company dedicated to developing light, radiation, sound and/or drug-activated small molecule compounds, associated drug formulations and the systems that activate them to destroy various cancers, bacteria and viruses Theralase stock has added 18.75 per cent year-over-year but remains down by 9.52 per cent since 2020 Theralase Technologies (TSXV:TLT), a healthcare stock focused on treating select cancers, bacteria and viruses, recently discovered that its lead drug candidate, Ruvidar, has the potential to inhibit deubiquitinating enzymes (DUBs), which are linked to certain cancers and neurodegenerative diseases. Ruvidar has been shown to induce oxidative stress in cancer cells through the production of Reactive Oxygen Species (ROS), facilitating their destruction without affecting healthy cells. The drug – alone and/or in combination with Transferrin to produce the compound Rutherrin -has delivered promising results against bladder cancer, lung cancer, as well as various viruses, including recent breakthroughs in the treatment of herpes. The chart below depicts Ruvidar's latest potential use-case as a DUBs inhibitor: Correlation between administration of Ruvidar and reduction in DUBs activity. According to Monday's news release, 'DUBs cause cellular damage by removing ubiquitin or ubiquitin-like molecules from target proteins.' These molecules are found in all eukaryotic cells – encompassing animals, plants and humans – playing 'an essential role in regulating gene expression, DNA repair, cytokine signaling, cell metabolism, cell cycle and cell death.' Theralase's study looks to build upon recent evidence that the alteration of DUBs is a key cause behind cancer drug resistance. Leadership insights 'Our latest research provides compelling evidence that Ruvidar not only induces oxidative stress through the production of ROS to destroy cancer cells, but also directly inhibits DUBs activity – a key host mechanism exploited by the cancer cell to evade immune defenses,' Mark Roufaiel, research scientist at Theralase, said in a statement. 'This dual mechanism positions Ruvidar as a promising therapeutic candidate, particularly against cancers, where traditional chemotherapeutics demonstrate limited effectiveness.' 'With the increasing prevalence of chemoradiotherapy-resistant cancers, Ruvidar, as an effective DUBs inhibitor, may be indispensable clinically to be used as a combinational therapy with various chemotherapy drugs and/or radiotherapy to provide a safe and effective treatment against various forms of chemoradiotherapy-resistant cancers,' commented Arkady Mandel, Theralase's chief scientific officer. 'The discovery of Ruvidar's effectiveness against DUBs is a notable milestone in the development of Theralase's small-molecule program and can be used for treating cancer, but could be expanded far beyond this to the treatment of age-associated medical conditions, various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Multiple Sclerosis, as well as to effectively combat various infectious diseases.' 'According to recent peer-reviewed research, reducing DUBs plays a very important role in the war against cancer and its innate ability to build up drug resistance,' added Roger DuMoulin-White, Theralase's president and chief executive officer. 'This latest research reinforces an additional mechanism of action beyond direct cancer destruction and indirect immune stimulation, stripping away one of cancer's final defence mechanisms. As Theralase pursues clinical development of Ruvidar for numerous cancers, such as brain and lung cancer, I look forward to reporting out on the clinical safety and efficacy of these programs.' About Theralase Technologies Theralase is a clinical-stage pharmaceutical company dedicated to developing light, radiation, sound and/or drug-activated small molecule compounds, associated drug formulations and the systems that activate them to destroy various cancers, bacteria and viruses. Theralase stock (TSXV:TLT) last traded at C$0.19 per share. The stock has added 18.75 per cent year-over-year but remains down by 9.52 per cent since 2020. Join the discussion: Find out what everybody's saying about this healthcare stock on the Theralase Technologies Inc. Bullboard and check out Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here. (Top image, generated by AI: Adobe Stock)
Associated Press
10-03-2025
- Health
- Associated Press
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser Therapy Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that interim clinical data for patients diagnosed with Parkinson's Disease ('PD') and treated with the Theralase® TLC-2400 Cool Laser Therapy ('CLT') system have improved both their motor and non-motor function. PD is a neurological condition, which affects the brain's ability to produce dopamine – the chemical which helps control movement. It is a progressive condition; whereby, symptoms appear gradually and slowly manifest, as the brain becomes increasingly damaged over time. There is no cure for PD, but the quality of life can be improved with various medications, surgery and lifestyle choices. 1 PD is the second-most common neurodegenerative disorder in the United States, with 90,000 people a year diagnosed and as many as 1 million Americans living with the disease. The cost of treatment is estimated to be $14 billion annually, while the combined direct and indirect cost; including: treatment, social security payments and lost income, is estimated to be nearly $52 billion per year. As the U.S. population ages, the number of people diagnosed with PD is expected to double by 2040. Worldwide there are more than 10 million people diagnosed with PD. 2,3 In January 2024, Theralase® donated two TLC-2400 Cool Laser Therapy ('CLT') systems to the University of Windsor to conduct a clinical study to aid in the research and development of a novel treatment for patients suffering from Parkinson's, an 'active' device with full power and a 'placebo' device with virtually no power. Theralase®'s CLT system, with super-pulsed laser technology, is one of the few technologies in the world that is able to non-invasively penetrate the human skull, promoting anti-inflammatory responses and stimulating neurons through the production of dopamine to increase neuromotor function. 4, 5 In the latest triple-blind, randomized, controlled, crossover clinical study, titled, " Effects of Cool Laser Therapy Treatment on Cognitive, Physical and Cerebral Neurovascular Function in Parkinson's Disease: A Pilot Study", patients were randomized to either an active or placebo Theralase® CLT system and provided 7 treatments, 3 times per week. After a 4 week 'wash-out' period to remove any residual effects, the patients were then 'crossed-over' to be treated with the device they had not received treatment from previously. At the end of each treatment cycle, patients were evaluated for both motor and non-motor assessments: Cognitive Ability (memory – non-motor) Neurovascular Coupling (brain blood flow – non-motor) Fine and Gross Neuromuscular Movement (physical movement – motor) For all figures, 'A' represents the Theralase® CLT system A and 'B' represents the Theralase® CLT system B; where, one system is active treatment and the other is placebo treatment. Each participant completed testing prior to ('Pre') and following ('Post') seven laser treatment sessions with each system. For all figures, the legend is as follows: [ This image cannot be displayed. Please visit the source: ] Figure 1. Montreal Cognitive Assessment To view an enhanced version of this graphic, please visit: The Montreal Cognitive Assessment ('MoCA') is a widely implemented non-motor screening tool used to assess cognitive dysfunction. MoCA scores range from 0 to 30; scores, with ≥ 26 indicating normal cognition and scores ≤ 25 indicating cognitive impairment. The average MoCA score increased by 11% from Pre A to Post A. The average MoCA score increased by 4% from Pre B to Post B. Figure 2. NeuroVascular Coupling To view an enhanced version of this graphic, please visit: NeuroVascular Coupling ('NVC') is a widely used non-motor assessment tool that evaluates the vascular component of neuronal health by measuring changes in cerebral blood velocity while stimulating specific brain regions corresponding to the imaged vessel. Enhanced blood flow in the brain regions that are stimulated signifies improved neuronal and vascular health. The average change in cerebral blood velocity during NVC was 14% greater from Pre A to Post A. The average change in cerebral blood velocity during NVC was 1% greater from Pre B to Post B. Figure 3. Orthostatic Tolerance Test To view an enhanced version of this graphic, please visit: The Orthostatic Tolerance Test ('OTT') is a motor assessment that assesses the ability to transition from laying down to standing up and remain standing in the upright position for five consecutive minutes. This figure illustrates the change in cerebral blood velocity from baseline to the first 30 seconds of standing. The average change in cerebral blood velocity during the OTT was 9% greater from Pre A to Post A. The average change in cerebral blood velocity during the OTT was unchanged from Pre B to Post B. Figure 4. Grooved Pegboard Test To view an enhanced version of this graphic, please visit: Grooved Pegboard Test ('GPT') is a commonly used motor assessment tool to assess fine motor control, hand-eye coordination and finger dexterity of participants. A lower time indicates improved motor control. The average time to complete the GPT using the dominant hand was reduced by 19% from Pre A to Post A. The average time to complete the GPT using the dominant hand was reduced by 6% from Pre B to Post B. Anecdotal Review: Participant 1: Participant 1 appeared to be thinking about his responses to the MoCA questions more intently during the Post A than Pre A session. They also appeared to have reduced hand tremors and improved memory during the Post A compared to the Pre A session. The participant and daughter, who attended each session, noted these improvements as well and inquired about continuing the laser treatments. Participant 2: During the Post A session, participant 2 noted that their sense of smell briefly returned and they noticed improvements in their gait (reduced shuffling) compared to the Pre A session. Participant 3: Participant 3 and significant other attended the Pre A and Post A sessions. The participant's significant other noticed several changes in the participant from Pre A to Post A; including, improved balance, mood and upper limb fine and gross motor control. Anthony Bain, Ph.D., principal investigator, University of Windsor is leading the clinical study together with Sean Horton, Ph.D.; Paula van Wyk, Ph.D.; Chad Sutherland, Ph.D.; Brooke Shepley, Ph.D. candidate and Luigi Albano, DC. Dr. Bain stated, ' We are extremely pleased that we have been able to demonstrate subjective and objective indications of neuromotor (motor and non-motor) functional improvement in the treatment of Parkinson's patients with the Theralase® CLT system. Preliminary results suggest an improvement in motor and non-motor function, with a reduction in symptoms according to both subjective and objective clinical evaluations. This has allowed these patients the opportunity to improve memory and perform tasks that they have struggled with for years. We are especially grateful to the collaboration with Theralase® on the project and for their generous donation of the CLT technology. ' Brooke Shepley, Ph.D. candidate, who specializes in cerebrovascular physiology and vascular biology at the University of Windsor, stated, " I am extremely encouraged by the response of the patients to the Theralase® CLT technology. The majority of patients who received the active arm of the study have responded well in most categories, after only a few treatments. It is evident, although the sample size of patients treated is small, that the Theralase® CLT seems to be quite effective in both motor and non-motor function in this patient population. I look forward to completing this pilot study and advancing to a larger clinical study to increase our sample size. ' Luigi Albano, D.C., President of Walkerville Chiropractic stated, " In the patients that I have treated in the clinical study to date, I and the patients themselves have seen significant improvements in their Parkinson's symptoms after only a short number of treatments. I look forward to expanding our clinical research to help more patients, whose mental retention and physical movements are at the mercy of this disease. CLT is non-invasive, highly effective and has no side effects. ' Arkady Mandel, M.D., Ph.D., Chief Scientific Officer at Theralase® stated, " Based on this pilot clinical study, Drs. Bain and Albano have clinically demonstrated that Theralase® CLT technology is well indicated in the safe and effective treatment of patients inflicted with neurodegenerative disorders, both motor and non-motor function; specifically, patients diagnosed with PD. The initial results of this clinical study indicate that the CLT treatment protocol is of benefit for patients in various stages of PD and as result will have a significant impact on their quality of life. CLT technology offers painless, non-invasive and effective drug-free solutions for these patients and I look forward to the day when Theralase® CLT technology will be recognized by every major industrialized nation in the world and available for healthcare practitioners to treat neurodegenerative diseases; including, Parkinson's Disease, particularly when so many conventional therapies and drugs have failed to produce sustainable effects or have led to unacceptable side effects. ' Roger DuMoulin-White, President and Chief Executive Officer of Theralase® stated, " Theralase® was pleased to donate our CLT technology to such a worthy cause as the research and development of a treatment for patients suffering from the symptoms of Parkinson's. Based on the recent success, Theralase® is planning to donate additional equipment to a new clinical study site to increase enrollment into the clinical study. Theralase® is excited by the recent results obtained by Drs. Albano and Bain, demonstrating remarkable improvements in Parkinson's symptoms, both motor and non-motor, with a significant reduction in tremors and dramatic increase in the ability of patients to ambulate and perform tasks that most of us take for granted, after only a few treatments. Our hope is that this clinical research leads to the widespread adoption of Theralase® CLT technology across the world for the benefit of all Parkinson's patients, suffering from this debilitating disease. ' 3 Statistics | Parkinson's Foundation 4 Deep brain light stimulation effects on glutamate and dopamine concentration - PMC 5 The potential of light therapy in Parkinson's disease | CPT About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains 'Forward-Looking Statements' ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations and medical devices. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's small molecules, their drug formulations and medical devices, through: preclinical research, clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals required to successfully commercialize various clinical studies in a timely fashion and implement its development plans. Other risks include the ability of the Company to: successfully commercialize its small molecule, their drug formulations and medical devices; access sufficient capital to fund the Company's operations on terms that are commercially favorable to the Company or at all; demonstrate that the Company's small molecule, their drug formulations and medical devices are effective against the diseases and conditions tested in its clinical studies; comply with the terms of license agreements with third parties in order not to lose the right to use key intellectual property in its business; protect its intellectual property; successfully submit, gain acceptance and approval of regulatory filings in a timely fashion. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in this press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. (5273) Kristina Hachey, CPA, X 224
